FDA Approves ImmunityBio's Anktiva To Treat Adults With Bacillus Calmette-Guerin Unresponsive Non-Muscle Invasive Bladder Cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-expanded-indication-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle
Share
Why It Matters
ImmunityBio got permission to sell a new cancer medicine. This shows the company can bring treatments to patients and grow its business.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.